Mankind Pharma inks in-licensing deal for Insulin Degludec in India

Mankind Pharma Limited has entered into an exclusive in-licensing and marketing agreement with China-based Chongqing Chenan Biopharmaceutical Co., Ltd. for the commercialization of Insulin Degludec and Insulin Degludec + Aspart Combination in India. This partnership aims to strengthen Mankind Pharma's presence in the diabetes segment and expand its injectable diabetes portfolio. The agreement aligns with Mankind Pharma's strategy of leveraging global innovation through strategic partnerships and in-licensing opportunities, particularly from China's growing biopharmaceutical sector. The company plans to enhance patient access to advanced diabetes therapies in India.